- Home
- APLT vs PERF Comparison
APLT vs PERF Comparison
Compare APLT & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PERF
- Stock Information
- Founded
- APLT 2016
- PERF 2015
- Country
- APLT United States
- PERF Taiwan
- Employees
- APLT N/A
- PERF N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PERF Computer Software: Prepackaged Software
- Sector
- APLT Health Care
- PERF Technology
- Exchange
- APLT Nasdaq
- PERF Nasdaq
- Market Cap
- APLT 178.6M
- PERF 205.7M
- IPO Year
- APLT 2019
- PERF N/A
- Fundamental
- Price
- APLT $1.28
- PERF $1.92
- Analyst Decision
- APLT Buy
- PERF
- Analyst Count
- APLT 5
- PERF 0
- Target Price
- APLT $4.13
- PERF N/A
- AVG Volume (30 Days)
- APLT 5.5M
- PERF 173.5K
- Earning Date
- APLT 11-10-2025
- PERF 10-28-2025
- Dividend Yield
- APLT N/A
- PERF N/A
- EPS Growth
- APLT N/A
- PERF 8.89
- EPS
- APLT N/A
- PERF 0.06
- Revenue
- APLT $121,000.00
- PERF $66,900,999.00
- Revenue This Year
- APLT N/A
- PERF $15.99
- Revenue Next Year
- APLT $5,935.35
- PERF $14.39
- P/E Ratio
- APLT N/A
- PERF $37.09
- Revenue Growth
- APLT N/A
- PERF 14.47
- 52 Week Low
- APLT $0.30
- PERF $1.51
- 52 Week High
- APLT $10.62
- PERF $3.44
- Technical
- Relative Strength Index (RSI)
- APLT 60.36
- PERF 49.46
- Support Level
- APLT $1.16
- PERF $1.94
- Resistance Level
- APLT $1.50
- PERF $2.10
- Average True Range (ATR)
- APLT 0.14
- PERF 0.09
- MACD
- APLT -0.02
- PERF 0.00
- Stochastic Oscillator
- APLT 61.64
- PERF 39.16
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.